Reported about 12 hours ago
INmune Bio announced that its Alzheimer's drug, XPro, did not enhance cognitive functions in early-stage patients during a mid-stage trial, leading to a nearly 63% drop in its stock price. Although the drug was found safe and well-tolerated, it failed to achieve its primary goal in the study involving 208 patients.
Source: YAHOO